Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Status Recruiting

Clinical Trial Summary

Participants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment with the NaviFUS System, guided by the neuronavigation system to evaluate the safety and efficacy of using NaviFUS System. During the treatment, the FUS will electronically scan and target to the assigned zones on one or both of the hippocampi. The study consists of a 60-day screening period for baseline observation prior to treatment, a FUS treatment period of 2 weeks for Cohort 1 or 3 weeks for Cohort 2 with 2 FUS treatments per week using the NaviFUS System, and a safety follow-up period of 81 days.

Clinical Trial Description

Up to 30% of patients with epilepsy are resistant to current anti-seizure medications, i.e. drug-resistant epilepsy (DRE). Resective surgery of the epileptogenic regions is the most effective option to treat patients with DRE. Unfortunately, up to 60% of DRE patients are not suitable for resective surgery. Neuromodulation approaches are increasingly being utilized in patients with DRE. The current approved techniques use invasive neuromodulation, which require complex neurosurgery and could cause side effects, such as infection, bleeding, and non-target brain tissue damage. Focused ultrasound is a novel, noninvasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with epilepsy. NaviFUS System (a neuro-navigation guided focused ultrasound system) is one of the FUS technologies that uses low-intensity focused ultrasound (LIFU) phased array system to deliver transcranial burst-mode ultrasound energy to induce neuromodulation effect and block signals in a specific area of the brain that cause symptoms of epilepsy such as seizures. The pilot clinical study has demonstrated that NaviFUS System safely delivered LIFU to the seizure onset zone and modulated the neuronal activity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05947656
Study type	Interventional
Source	Genovate Biotechnology Co., Ltd.,
Contact	Caitlin Roberts, Ms.
Phone	+61 3 9076 2598
Email	cai.roberts@alfred.org.au
Status	Recruiting
Phase	N/A
Start date	October 2, 2023
Completion date	May 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04378075` - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy	Phase 2/Phase 3
Recruiting	`NCT05928598` - Goals for Epilepsy Clinic Visits Trial	N/A
Recruiting	`NCT05539287` - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy	Phase 2
Not yet recruiting	`NCT04601974` - Lentiviral Gene Therapy for Epilepsy	Phase 1/Phase 2
Completed	`NCT02982824` - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy	N/A
Recruiting	`NCT05485558` - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy	Phase 2
Not yet recruiting	`NCT04553354` - Cortical Resections in Drug Resistant Epilepsy
Recruiting	`NCT04999046` - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy	N/A
Recruiting	`NCT04714996` - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy	Phase 2
Recruiting	`NCT04839601` - RNS System RESPONSE Study	N/A
Recruiting	`NCT06059157` - Epileptogenic Network Visualisation With Advanced MRI	N/A
Recruiting	`NCT05393518` - Electroclinical Correlation of Anxiety	N/A
Not yet recruiting	`NCT05555537` - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed	`NCT03419000` - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY	N/A
Enrolling by invitation	`NCT06341075` - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy	N/A
Not yet recruiting	`NCT05527093` - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy	N/A
Recruiting	`NCT05697614` - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children	Phase 4
Recruiting	`NCT06309251` - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Not yet recruiting	`NCT06340802` - A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl	N/A
Completed	`NCT03860298` - Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.